Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy

Mark Gurney; Anmol Baranwal; Allison Rosenthal; Mohamed A Kharfan-Dabaja; Saad S Kenderian; Yi Lin; Mithun Vinod Shah

doi:10.1001/jamaoncol.2023.7182

Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy

JAMA Oncol. 2024 Apr 1;10(4):532-535. doi: 10.1001/jamaoncol.2023.7182.

Authors

Mark Gurney¹, Anmol Baranwal^{1

2}, Allison Rosenthal³, Mohamed A Kharfan-Dabaja⁴, Saad S Kenderian¹, Yi Lin¹, Mithun Vinod Shah¹

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, Minnesota.
² Cancer Centers of Southwest Oklahoma, Lawton.
³ Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona.
⁴ Department of Hematology/Oncology, Mayo Clinic, Jacksonville, Florida.

PMID: 38386311
PMCID: PMC10884941 (available on 2025-02-22)
DOI: 10.1001/jamaoncol.2023.7182

No abstract available

Plain language summary

This case-control study examines the incidence and risks of myeloid neoplasms in adults treated for B-cell lymphoproliferative disorders or multiple myeloma.

MeSH terms

Cell- and Tissue-Based Therapy
Humans
Immunotherapy, Adoptive
Multiple Myeloma* / therapy
Neoplasms*
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen*
T-Lymphocytes

Substances

Receptors, Chimeric Antigen
Receptors, Antigen, T-Cell

Grants and funding

P50 CA186781/CA/NCI NIH HHS/United States